Adaptive Phase II Trials

Boris Freidlin () and Edward L. Korn ()
Additional contact information
Boris Freidlin: National Cancer Institute, Biometric Research Program, Division of Cancer Treatment and Diagnosis
Edward L. Korn: National Cancer Institute, Biometric Research Program, Division of Cancer Treatment and Diagnosis

Chapter 61 in Principles and Practice of Clinical Trials, 2022, pp 1133-1144 from Springer

Abstract: Abstract Phase II trials are designed to obtain preliminary efficacy information about a new therapy in order to assess whether the new therapy should be tested in definitive (phase III) trials. Adaptive trial designs allow the design of a trial to be changed during its conduct, possibly using accruing outcome data. Adaptations to phase II trials considered in this chapter include formal interim monitoring, phase II/III trial designs, adaptations related to biomarker subgroups, sample size reassessment, outcome-adaptive randomization, and adaptive pooling of outcome results across patient subgroups. Adaptive phase II trials allow for the possibility of trials reaching their conclusions earlier, with more patients being treated with therapies that have activity for them.

Keywords: Biomarkers; Futility monitoring; Interim monitoring; Outcome-adaptive randomization; Phase II/III; Sample size reassessment (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-319-52636-2_276

Ordering information: This item can be ordered from
http://www.springer.com/9783319526362

DOI: 10.1007/978-3-319-52636-2_276

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().